AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00783380 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Subunit influenza vaccine
Description: Influvac 2005/2006, Solvay Pharma AG, Bern, Switzerland Assigned to all 4 groups if immunocompromized patients
Study NCT01473693 — intervention group
Intervention type: OTHER
Intervention: MRI Screening Form, MRI, Demographic / Medical Data form
Description: MRI Screening Form: MRI screening form will be administered twice at baseline and follow up visits. Administration time: 5 minutes. MRI data: at both time points (pre- and post-treatment only) Administration time: 30 minutes.~Demographic / Medical Data: Administration time: 5 minutes.
Study NCT01473693 — intervention group
Intervention type: OTHER
Intervention: MRI Screening Form, MRI. Demographic / Medical Data
Description: MRI Screening Form: MRI screening form will be administered twice at baseline and follow up visits Administration time: 5 minutes.~MRI data: at both time points (pre- and post-treatment only) Administration time: 30 minutes.~Demographic / Medical Data: Administration time: 5 minutes
Study NCT00825422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine / Placebo
Description: Wound infiltration with local anesthesics/placebo through a parietal paravertebral catheter
Study NCT00825422 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine / Placebo
Description: Wound infiltration with local anesthesics/placebo through a parietal paravertebral catheter
Study NCT01855217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: 1 mg/kg total BW based sugammadex reversal of deep block
Study NCT01855217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: 1 mg/kg ideal BW based sugammadex reversal of deep block
Study NCT01855217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0,9% NaCl
Study NCT03467932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort A: ORMD-0801
Description: Part 1 In the first two weeks of active treatment (Part 1) subjects will receive double-blind therapy according to their randomized regimen (placebo or ORMD-0801) to be taken QHS, BID or TID. Subjects will undergo a step-wise dose escalation from a starting dose of 16 mg (Visit 3), to 24 mg (Visit 4), to a top dose of 32 mg (Visit 5 onward). Subjects will then enter Part 2.~Part 2:~During Part 2, subjects will remain on fixed doses of ORMD-0801 (or matched placebo) for 10 weeks. Doses will not be adjusted unless clinically indicated for adverse events or hypoglycemia.
Study NCT03467932 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo provided QHS, BID, TID
Study NCT03467932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort B: ORMD-0801
Description: Part 1 In the first two weeks of active treatment, subjects will receive double-blind therapy according to their randomized regimen (ORMD 0801 8 mg or 16 mg, or matched placebo) to be taken QHS or BID. Subjects will then enter Part 2 at the same dose and regimen administered in Part 1.~Part 2 Subjects will remain on fixed doses of ORMD-0801 (or matched placebo) for 10 weeks. Doses will not be adjusted unless clinically indicated for adverse events or hypoglycemia.
Study NCT01534325 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SD
Description: The participants in the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the device under study (called SD). During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference.~The use of the SD device is done by study participants during the day every day throughout the study period. The device under study can be easily used by the participants themselves in their regular environment and does not require professional assistance.~The device under study is expected to affects the satiety, energy homeostasis and metabolic control centers in the brain and by that to reduce food intake and lead to weight loss.~The device under study is a device- not a medication and not a surgical procedure, and it does not involve any of such elements.
Study NCT01534325 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: The participants in the Control arm of the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the placebo. During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference.~The use of the placebo is done by the control study participants during the day every day throughout the study period. The placebo can be easily used by the participants themselves in their regular environment and does not require professional assistance.
Study NCT03017430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 600 mg a day for six-seven days along with symptomatic therapy: Doxylamin 30 mg/day, Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine).
Study NCT03017430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: Clonidine 600 micrograms a day for six-seven days along with symptomatic therapy: Doxylamin 30 mg/day, Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)
Study NCT03017430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxylamin
Study NCT05021016 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)
Description: The EpiVacCorona vaccine is intended to prevent COVID-19. The vaccine relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant (aluminum hydroxide).~The vaccine induces the specific immunity against the SARS-CoV-2 coronavirus following two intramuscular injections spaced 21 to 28 days apart.~The EpiVacCorona vaccine contributes to the development of protective immunity against SARS-CoV-2 coronavirus following two intramuscular administrations given 21 to 28 days apart.
Study NCT03955913 — intervention group
Intervention type: OTHER
Intervention: Archival Tumor Tissue Sample
Description: Percentage of participants with UC and selected FGFR aberrations will be assessed through molecular testing of their archival tumor tissue.
Study NCT02497443 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells
Description: Autologous bone marrow-derived mesenchymal stem cells, expanded ex vivo and neuroinduced (a portion of the cells). The final autologous cultured MSCs (0.7 -1.4 x 106 cells/kg of weigh) and autologous neuroinduced MSCs (0.04 - 0.1 x 106 cells/kg of weigh) were used for intravenous administration (cultured MSCs) and a subsequent endolumbal injection (neuroinduced MSCs) one week later in the patients in an autologous manner.
Study NCT00886743 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: oprelvekin
Description: injection, 50 mg/kg, once daily
Study NCT01416974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Patients will first receive a single infusion of therapy conditioning with cyclophosphamide.
Study NCT01416974 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: modified T cells
Description: followed by consolidative therapy with the modified T cells in 3 planned cohorts.
Study NCT00577980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Initial dose of Testosterone 200 mg IM administered followed by 200 mg - 400 mg every 2 weeks.
Study NCT04240717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Decision Aid
Description: The Patient Decision Aid is an interactive, web-based tool that provides information on advanced melanoma and its treatment options with a strong focus on immunotherapies (i.e. response to therapy, risk of side effects).
Study NCT04116060 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Nitrate
Description: Oral dietary nitrate supplementation with (0,12 mmol/kgBW sodium-nitrate)
Study NCT04116060 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo Comparator: Dietary sodium-chloride dissolved in water (0,12 mmol sodium-chloride/kgBW/day)
Study NCT04641325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention Group
Description: Patients will be educated on methods of self-evaluating exertion and cardiovascular effort by assessing respiratory rate and perceived exertion. Next, patients will be given options for cardiovascular activities and complete at a moderate level of activity for a minimum of 150 minutes per week. Patients will perform a combination of exercises under the supervision of a physical therapist until a mod intensity level is reached and sustained. Patients will be taught to use the activity tracker to record their heart rate, activity, and PES. Patients will have a phone call every week to assess status, answer questions, and provide guidance on progressing intensity or duration of exercise. At the end of 8 weeks all patients will return for re-assessment.
Study NCT03836950 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagVenture MagProX100 stimulator (MagVenture, Falun, Denmark)
Description: The coil will be held tangentially to the skull at approximately 45º from the midline. One rTMS session will consist of 40 trains of 5sec each at 110% of resting motor threshold and 15Hz will be provided at the left DLPFC.
Study NCT01536535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Corticosteroids
Description: Treatment with oral corticosteroids
Study NCT01536535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional Therapies
Description: Anti-TNFα, Calcineurin inhibitor, Immunomodulator
Study NCT03836950 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: MagVenture MagProX100 stimulator (MagVenture, Falun, Denmark)
Description: The coil will be held tangentially to the skull at approximately 45º from the midline. The sham coil will not release any stimulation, but it will look, feel and sound like the real rTMS
Study NCT03017430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxylamin
Study NCT01536535 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colectomy
Description: Colectomy
Study NCT03017430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)
Study NCT03017430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)
Study NCT01851174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Patients will receive Gemcitabine (1,000 mg/m\^2) IV over 30 minutes after nab-paclitaxel infusion
Study NCT01851174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Patients will receive nab-Paclitaxel (125 mg/m\^2) IV over 30 minutes before Gemcitabine infusion
Study NCT03692338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Patients will be asked to complete 3 x 30 minute exercise sessions each week.
Study NCT00262795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine i.v. (25 mg/m2/d, d1-5) q28d; max 6 cycles
Study NCT00262795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorambucil
Description: Chlorambucil p.o. (0,4 mg - max. 0,8 mg/kg/d, d1) q15d, max. 12 month
Study NCT01984580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zinc gluconate
Description: 26.6 mg zinc BID (as zinc gluconate)
Study NCT03143725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972
Description: Oral administration of GLPG1972 in four different treatment conditions (Treatments A throug D)
Study NCT03340402 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated Partial Breast Irradiation
Description: Proton radiation
Study NCT03340402 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AlignRT
Description: AlignRTTM uses infrared imaging to capture the 3D data of the patient's position to ensure accuracy of treatment delivery
Study NCT04073264 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: monofilament
Description: In the intervention group,monofilament absorbable suture,will be used.
Study NCT04073264 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: monofilament
Description: In the intervention group,monofilament absorbable suture,will be used.
Study NCT01463956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: Boceprevir 200 mg capsules at 2400mg/day (800mg 3 times a day) from week 4 until week 48 or until liver transplant (can be performed from week 16)
Study NCT01463956 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peg-Interferon α-2b or Peg-Interferon α-2a
Description: Peg-Interferon α-2b by subcutaneous injection, 1.5µg/kg/week, from day 0 until week 48 or until liver transplantation, or Peg-Interferon α-2a by subcutaneous injection, 180 µg, once weekly, from day 0 until week 48 or until liver transplantation
Study NCT01463956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin: capsules 200 mg (weight-based daily dose: \<65kg, 800 mg; 65-80kg, 1000mg; 81-105kg: 1200mg; >105kg: 1400mg), from day 0 until week 48 or until liver transplantation or, Ribavirin: Tablet Oral, weight-based dose, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over75 kg, once daily, from day 0 until week 48 or until liver transplantation
Study NCT02835339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate 4g loading dose, 1g/hr infusion
Study NCT02835339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 6g loading dose, 2g/hr infusion
Study NCT01216111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Cisplatin
Description: Paclitaxel 80 mg/m2 D1，8，15 Cisplatin AUC=2 D1，8，15~1 cycle = 28days~PC\*6
Study NCT01216111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil epirubicin cyclophosphamide and docetaxel (FEC-T)
Description: fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2 intravenously on day 1 every 21 days for three cycles followed by docetaxel 100 mg/m2 intravenously
Study NCT01565083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Loading dose of 840 mg on Day 1 of first 21-day cycle, followed by 420 mg on Day 1 of each subsequent cycle.
Study NCT03789578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0148-0287sema
Description: Study staff will inject NNC0148-0287sema, 175unit (U)/0.5 mg in the morning after fasting under the skin of participants' thigh using a needle and a pen.
Study NCT03789578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Study staff will inject semaglutide, 0.5 mg alone in the morning after fasting under the skin of participants' thigh using a needle and a pen.
Study NCT03789578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0148-0287
Description: Study staff will inject insulin 287 (NNC0148-0287), 175U alone in the morning after fasting under the skin of participants' thigh using a needle and a pen.
Study NCT03723161 — intervention group
Intervention type: DEVICE
Intervention: Bone Achored Hearing surgery
Description: This is a observational study of pediatric patients undergoing bone anchored hearing surgery. The collected data will be used to assess the implant stability development of the Ponto BHX implant during up tp 24 months after implantation in a pediatric population undergoing bone anchored hearing surgery.
Study NCT01565083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Loading dose of 8 mg/kg on Day 1 of first 21-day cycle, followed by 6 mg/kg on Day 1 or 2 of each subsequent cycle.
Study NCT01565083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: A dose of 25 mg/m\^2 followed by 30-35 mg/m\^2 on Days 2 and 9 of the first 21-day cycle and on Days 1 and 8 (or Days 2 and 9) of each subsequent cycle.
Study NCT02320474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Study NCT01501799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adapalene 0.1% and benzoyl peroxide 2.5% topical gel
Description: Dosage form: topical gel Dosage: A pea-sized amount was applied to each affected area of the face Frequency: once daily in the evening Duration: 12 weeks
Study NCT01501799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPIDUO
Description: EPIDUO (adapalene 0.1% and benzoyl peroxide 2.5%) Gel
Study NCT01501799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Vehicle Gel)
Description: Vehicle Gel
Study NCT02946957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy for Insomnia
Description: Six telephone sessions that last 20-30 minutes presenting cognitive behavioral therapy for insomnia.
Study NCT02946957 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Only Control
Description: Six telephone sessions that last 20-30 minutes presenting sleep and osteoarthritis education.
Study NCT03229863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sweet Potatos
Description: Plum Organics, Just Sweet Potato
Study NCT03229863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pears
Description: Earth's Best, First Pears
Study NCT04176419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.25 mg/kg IV bolus before incision, followed by 0.005 mg/kg/minute IV for the remainder of the surgical case excluding the final 30-45 minutes.
Study NCT04176419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ketamine
Description: 0.25 mg/kg IV bolus before incision, followed by 0.005 mg/kg/minute IV for the remainder of the surgical case excluding the final 30-45 minutes.
Study NCT04176419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 1.5 mg/kg IV bolus before incision, followed by infusion of 1.5 mg/kg/hour ideal body weight (max 8 hours) during the case
Study NCT04176419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Lidocaine
Description: 1.5 mg/kg IV bolus before incision, followed by infusion of 1.5 mg/kg/hour ideal body weight (max 8 hours) during the case
Study NCT04176419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 1,000 mg orally at time of check-in to the preoperative unit
Study NCT04176419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Acetaminophen
Description: 1,000 mg orally at time of check-in to the preoperative unit
Study NCT04176419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 600 mg orally at time of check in to the preoperative unit
Study NCT04176419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gabapentin
Description: 600 mg orally at time of check in to the preoperative unit
Study NCT04176419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200 mg orally at time of check in to the preoperative unit
Study NCT04176419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Celecoxib
Description: 200 mg orally at time of check in to the preoperative unit
Study NCT02516566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP
Description: Mechanical ventilation with PEEP 8 cmH2O
Study NCT02680795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat IV
Description: Cohort A:~Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.~Cohort B:~Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.~Cohort C:~Belinostat 750mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.
Study NCT02691897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin 3mg once daily at bedtime
Study NCT02691897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 tablet once daily at bedtime
Study NCT00736320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABVD (Adriamycin, Bleomycin, Vincristine, Dacarbazine)
Description: chemotherapy with 2 cycles of ABVD (day 1 + 15)
Study NCT00736320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABVD (Adriamycin, Bleomycin, Vincristine, Dacarbazine)
Description: chemotherapy with 2 cycles of ABVD (day 1 + 15)
Study NCT00736320 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 20 Gy IFRT (Involved Field Radiotherapy)
Description: 20 Gy Involved Field Radiotherapy
Study NCT00736320 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 20 Gy IFRT (Involved Field Radiotherapy)
Description: 20 Gy Involved Field Radiotherapy
Study NCT00525109 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No intervention